In people with obesity and prediabetes, a drug called sitagliptin increases certain gut hormones but does not improve how the body responds to insulin or lower fasting blood sugar. This suggests that...
Mechanism
Synthesis from 1 study
A drug that directly activates GLP-1 receptors lowers blood sugar by stopping the liver from making too much glucose and helping muscles absorb more sugar. Just making the body produce more of its own GLP-1 hormone doesn't work — the drug has to bind tightly and for longer to trigger the right...
Most probable mechanism
A drug that directly turns on GLP-1 receptors in the liver and muscles lowers blood sugar by telling the liver to make less glucose and helping muscles take up more glucose. Just making the body produce more of its own GLP-1 hormone doesn't do this — the drug has to physically bind to the receptor to trigger the right signals.
Pharmacologic GLP-1 receptor agonists bind with high affinity and duration to GLP-1 receptors on pancreatic alpha cells, triggering intracellular signaling that suppresses glucagon secretion.
Reduced glucagon secretion decreases hepatic glucose production through diminished activation of gluconeogenesis and glycogenolysis pathways.
Pharmacologic GLP-1 receptor agonists activate distinct downstream signaling pathways (e.g., pERK1/2) in hepatocytes and peripheral tissues that enhance glucose uptake and reduce insulin resistance.
Improved glucose homeostasis reduces the demand for compensatory hyperinsulinemia, unmasking enhanced insulin sensitivity without altering beta-cell secretory capacity.
Evidence from Studies
Supporting (1)
Community contributions welcome
Weight Loss-Independent Effect of Liraglutide on Insulin Sensitivity in Individuals with Obesity and Pre-Diabetes.
Contradicting (0)
Community contributions welcome
Gold Standard Evidence Needed
According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.